News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
381,705 Results
Type
Article (25922)
Company Profile (59)
Press Release (355724)
Multimedia
Podcasts (25)
Webinars (7)
Section
Business (104258)
Career Advice (449)
Deals (16872)
Drug Delivery (51)
Drug Development (47594)
Employer Resources (47)
FDA (12262)
Job Trends (8440)
News (185923)
Policy (19424)
Tag
Academia (1750)
Accelerated approval (3)
Adcomms (8)
Allergies (73)
Alliances (26743)
ALS (57)
Alzheimer's disease (811)
Antibody-drug conjugate (ADC) (51)
Approvals (12326)
Artificial intelligence (169)
Autoimmune disease (10)
Automation (4)
Bankruptcy (142)
Best Places to Work (6892)
BIOSECURE Act (5)
Biosimilars (36)
Biotechnology (39)
Bladder cancer (59)
Brain cancer (17)
Breast cancer (192)
Cancer (1430)
Cardiovascular disease (119)
Career advice (407)
Career pathing (13)
CAR-T (70)
Cell therapy (199)
Cervical cancer (13)
Clinical research (40513)
Collaboration (439)
Compensation (126)
Complete response letters (9)
COVID-19 (1493)
CRISPR (12)
C-suite (139)
Cystic fibrosis (42)
Data (1525)
Decentralized trials (2)
Denatured (17)
Depression (30)
Diabetes (174)
Diagnostics (3521)
Digital health (11)
Diversity (5)
Diversity, equity & inclusion (13)
Drug discovery (52)
Drug pricing (54)
Drug shortages (21)
Duchenne muscular dystrophy (55)
Earnings (36913)
Editorial (20)
Employer branding (6)
Employer resources (44)
Events (51799)
Executive appointments (447)
FDA (13249)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (3)
Frontotemporal dementia (3)
Funding (402)
Gene editing (36)
Generative AI (10)
Gene therapy (126)
GLP-1 (401)
Government (3035)
Grass and pollen (3)
Guidances (42)
Healthcare (12186)
Huntington's disease (10)
IgA nephropathy (16)
Immunology and inflammation (40)
Indications (19)
Infectious disease (1563)
Inflammatory bowel disease (79)
Inflation Reduction Act (4)
Influenza (26)
Intellectual property (50)
Interviews (40)
IPO (7038)
IRA (19)
Job creations (1839)
Job search strategy (378)
Kidney cancer (7)
Labor market (10)
Layoffs (169)
Leadership (4)
Legal (3632)
Liver cancer (57)
Lung cancer (232)
Lymphoma (100)
Machine learning (3)
Management (17)
Manufacturing (104)
MASH (48)
Medical device (12906)
Medtech (12909)
Mergers & acquisitions (10123)
Metabolic disorders (432)
Multiple sclerosis (54)
NASH (11)
Neurodegenerative disease (49)
Neuropsychiatric disorders (9)
Neuroscience (1144)
NextGen: Class of 2025 (3930)
Non-profit (2822)
Now hiring (16)
Obesity (218)
Opinion (70)
Ovarian cancer (52)
Pain (64)
Pancreatic cancer (53)
Parkinson's disease (88)
Partnered (11)
Patents (112)
Patient recruitment (82)
Peanut (37)
People (34715)
Pharmaceutical (17)
Pharmacy benefit managers (11)
Phase I (11605)
Phase II (17533)
Phase III (14414)
Pipeline (686)
Policy (59)
Postmarket research (1668)
Preclinical (3615)
Press Release (18)
Prostate cancer (76)
Psychedelics (17)
Radiopharmaceuticals (160)
Rare diseases (183)
Real estate (2846)
Recruiting (16)
Regulatory (14212)
Reports (16)
Research institute (1607)
Resumes & cover letters (48)
Rett syndrome (2)
RNA editing (2)
RSV (20)
Schizophrenia (51)
Series A (66)
Series B (48)
Service/supplier (3)
Sickle cell disease (21)
Special edition (3)
Spinal muscular atrophy (102)
Sponsored (13)
Startups (2120)
Stomach cancer (8)
Supply chain (38)
Tariffs (11)
The Weekly (8)
Vaccines (353)
Venture capitalists (13)
Weight loss (141)
Women's health (17)
Worklife (4)
Date
Today (60)
Last 7 days (461)
Last 30 days (1398)
Last 365 days (18452)
2025 (5888)
2024 (19849)
2023 (22736)
2022 (30680)
2021 (32985)
2020 (32192)
2019 (28413)
2018 (21810)
2017 (18906)
2016 (18113)
2015 (21195)
2014 (16023)
2013 (13241)
2012 (14349)
2011 (14622)
2010 (13181)
Location
Africa (354)
Alabama (17)
Alaska (2)
Arizona (118)
Arkansas (10)
Asia (24550)
Australia (3887)
California (3049)
Canada (1218)
China (372)
Colorado (165)
Connecticut (172)
Delaware (115)
Europe (47927)
Florida (542)
Georgia (126)
Idaho (33)
Illinois (358)
India (14)
Indiana (223)
Iowa (3)
Japan (119)
Kansas (73)
Kentucky (12)
Louisiana (7)
Maine (27)
Maryland (634)
Massachusetts (2134)
Michigan (107)
Minnesota (270)
Mississippi (2)
Missouri (52)
Montana (18)
Nebraska (18)
Nevada (33)
New Hampshire (60)
New Jersey (1124)
New Mexico (9)
New York (953)
North Carolina (553)
North Dakota (4)
Northern California (1334)
Ohio (131)
Oklahoma (3)
Oregon (23)
Pennsylvania (824)
Puerto Rico (7)
Rhode Island (24)
South America (520)
South Carolina (21)
Southern California (1169)
Tennessee (77)
Texas (537)
United States (12764)
Utah (111)
Virginia (80)
Washington D.C. (39)
Washington State (228)
West Virginia (3)
Wisconsin (42)
381,705 Results for "anamar medical".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Policy
AnaMar Announces US and EU Orphan Drug Designation for AM1476 for Treating Systemic SclerosisFirst-in-class, peripheral-acting serotonin receptor antagonist being developed as an anti-fibrotic treatment for systemic sclerosis
AnaMar, a clinical-stage biotech company developing first-in-class anti-fibrotic 5-HT2B receptor antagonists, announces that the European Medicines Agency and the United States Food and Drug Administration have granted orphan drug designation to its lead clinical candidate, AM1476 for the treatment of systemic sclerosis.
February 5, 2024
·
4 min read
Drug Development
AnaMar Announces Positive Phase I Data for its Phase II Ready Compound AM1476 for Treating Fibrosis
AnaMar, a clinical-stage biotech company developing a first-in-class, peripheral 5-HT2B receptor antagonist, AM1476, as a pan anti-fibrotic medicine, announces positive results from its Phase I study, and the completion of Phase II enabling pre-clinical studies for its initial orphan indication in systemic sclerosis characterized by lung and skin fibrosis.
May 23, 2023
·
4 min read
Press Releases
Tenon Medical(R) Receives Approval for Notice of Allowance from the European Patent Office
March 11, 2025
·
2 min read
Press Releases
Tenon Medical(R) Announces FDA Clearance of Catamaran(R) SI Joint Fusion System for New Indication to Augment Spinal Fusion
March 24, 2025
·
2 min read
Press Releases
Tenon Medical(R) to Host Meetings During the 2025 J.P. Morgan Healthcare Conference in San Francisco
January 9, 2025
·
2 min read
Press Releases
AVITA Medical to Announce First Quarter 2025 Financial Results
April 17, 2025
·
1 min read
Press Releases
Peijia Medical collaborates with dsm-firmenich to create groundbreaking innovative medical device products
April 1, 2025
·
4 min read
Press Releases
First Patient Enrolled in Merit Medical’s PREEMIE Study
March 10, 2025
·
3 min read
Press Releases
AVITA Medical to Host Acute Wound Care Showcase on May 13, 2025
April 24, 2025
·
2 min read
Press Releases
Envoy Medical Reports on First Quarter 2025 Results
Company Provides Update on Its Pivotal Clinical Study for Fully Implanted Cochlear Implant
May 1, 2025
·
13 min read
1 of 38,171
Next
